Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia

Jenna Rossoff*, Christina Baggott, Snehit Prabhu, Holly Pacenta, Christine L. Phillips, Heather Stefanski, Julie An Talano, Amy Moskop, Steven P. Margossian, Michael R. Verneris, Gary Douglas Myers, Nicole Karras, Patrick A. Brown, Muna Qayed, Michelle Hermiston, Prakash Satwani, Christa Krupski, Amy K. Keating, Rachel Wilcox, Cara A. RabikVanessa A. Fabrizio, Michael Kunicki, Vasant Chinnabhandar, A. Yasemin Goksenin, Kevin J. Curran, Crystal L. Mackall, Theodore W. Laetsch, Liora M. Schultz

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

7 Scopus citations
Original languageEnglish (US)
Pages (from-to)2138-2142
Number of pages5
JournalBlood
Volume138
Issue number21
DOIs
StatePublished - Nov 25 2021

Funding

Conflict-of-interest disclosure: C.L.P. has served on an advisory committee for Novartis. H.S. has served on an advisory committee and as a member of the Speakers Bureau for Novartis. S.P.M. has served on an advisory committee for Novartis and Jazz Pharmaceuticals. M.R.V. has served on an advisory committee for Novartis, has been a consultant for and is a current equity holder in Fate Therapeutics and B-MoGen Biotechnologies, and has been a consultant for UpToDate. G.D.M. has served on the ELIANA trial Steering Committee and Speakers Bureau and has served as a consultant and received honoraria from Novartis. P.A.B. has served on an advisory committee for Novartis, Kite, Takeda, Janssen, Kura, Servier, and Jazz Pharmaceuticals. M.Q. has served as a consultant for Novartis and Mesoblast. M.H. has served on an advisory board for Sobi and Novartis. P.S. has served as a consultant for Takeda and Mesoblast. K.J.C. has served as a consultant for and received research funding from Novartis, has served as a consultant for Mesoblast, and received research funding from Celgene. C.L.M. has served as a consultant for and is a current equity holder in Lyell Immunopharma and Apricity Health, has served as a consultant for NeoImmune Tech, Nektar Therapeutics, and Bristol Myers Squibb, and is a current equity holder in Allogene. T.W.L. reports consultancy relationships with Novartis, Cellectis, Bayer, Deciphera, Jumo Health, and Y-mAbs Therapeutics and has received research funding from Pfizer, Novartis, and Bayer. The remaining authors declare no competing financial interests.

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this